Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) represents a worldwide health challenge, ranking globally as the third most common cause of cancer-related mortality. Current advancements in the HCC therapeutic armamentarium succeeded in challenging HCC conventional therapy. Systemic therapies includi...

Descripción completa

Detalles Bibliográficos
Autores principales: Atwa, Sara M., Odenthal, Margarete, El Tayebi, Hend M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430643/
https://www.ncbi.nlm.nih.gov/pubmed/34503153
http://dx.doi.org/10.3390/cancers13174343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430643/
https://www.ncbi.nlm.nih.gov/pubmed/34503153
http://dx.doi.org/10.3390/cancers13174343

Ejemplares similares